Loading
A phase 1/2 trial of lurbinectedin and osimertinib in lung cancer, run by Misty Shields, now recruiting.
Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer is a phase 1/2, interventional study registered as NCT07153055 by Misty Shields, with a registry enrolment figure of 16 participants, started 2026-08 and due to reach its primary completion in 2029-04. Interventions recorded: Lurbinectedin; Osimertinib. Conditions listed: Small Cell Lung Cancer ( SCLC ); Transformed Small Cell Lung Cancer. Primary outcome: Grade 3 or dose-limiting toxicities. Lung eligibility wording from the registry: "Must have a histologically or cytologically confirmed transformation to small cell lung carcinoma/cancer". Sites: United States. No results are recorded here; the registry entry is the source.
Shares Lurbinectedin, Lung cancer trials open today (registry snapshot), Small-cell lung cancer, Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Osimertinib, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Osimertinib, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors, Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Small-cell lung cancer, Small-molecule kinase inhibitors, Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Osimertinib, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Lurbinectedin, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Osimertinib, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors, Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Osimertinib, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.